STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #950 by analyst upside · 2026-06-27
SNDX
Syndax Pharmaceuticals, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+83.0%
implied upside to consensus target
Current Price $21.31
Consensus Target $39.0
Bull Target $57.0
Bear Target $29.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
10
Hold
0
Sell
0
52-Week Low $8.59
52-Week High $25.59
YTD Return +0.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -40.7x
EPS (TTM) $-2.79
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $217M
Profit Margin -112.0%
52-WEEK RANGE
52-Week Low $8.59
52-Week High $25.59
Current Price $21.31
Bear Target $29.0
Bull Target $57.0
● Now $21.31 ● Target $39.0
TRADING DATA
Avg Volume 1.7M
YTD Return +0.0%
Analyst Count 12
Consensus Buy
Upside to Target +83.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Syndax Pharmaceuticals, Inc. (SNDX) is currently trading at $21.31 with a Wall Street consensus price target of $39.0, implying potential upside of 83.0% over the next 12 months. 12 analysts currently cover SNDX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $57.0, while the most cautious has a target of $29.0.

SNDX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 0.0% year-to-date and is currently trading near the upper end of its 52-week range of $8.59 – $25.59.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SNDX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-12 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-22 31% win rate (48 calls)
UBS — Reiterated
Buy → Buy 2026-05-13 33% win rate (6 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-01 Building track record
Goldman Sachs — Reiterated
Buy → Buy 2026-04-01 Building track record
Mizuho — Reiterated
Outperform → Outperform 2026-03-31 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-09 43% win rate (7 calls)
Citigroup — Reiterated
Buy → Buy 2026-03-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
20/30
Consensus clarity
4/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →